LifeStance Health (LFST) Cash & Equivalents (2020 - 2026)

LifeStance Health (LFST) has 7 years of Cash & Equivalents data on file, last reported at $76.9 million in Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $76.9 million, down 42.74% year-over-year; the trailing twelve-month figure through Mar 2026 was $76.9 million (down 42.74% YoY), and the FY2025 annual result was $175.5 million, up 45.19% from the prior year.
• Cash & Equivalents slipped to $76.9 million in Q1 2026 per LFST's latest filing, from $175.5 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $175.5 million in Q4 2025 and troughed at $28.5 million in Q3 2023.
• A 5-year average of $96.5 million and a median of $96.7 million in 2022 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2023 and 2025: Cash & Equivalents slumped 68.47% in 2023, then soared 314.62% in 2025.
• A 5-year view of Cash & Equivalents shows it stood at $108.6 million in 2022, then tumbled by 37.68% to $67.7 million in 2023, then jumped by 78.57% to $120.9 million in 2024, then jumped by 45.19% to $175.5 million in 2025, then sank by 56.17% to $76.9 million in 2026.
• Business Quant data shows LFST's Cash & Equivalents at $76.9 million in Q1 2026, $175.5 million in Q4 2025, and $141.8 million in Q3 2025.